Abstract
Since intravesical recurrence of superficial bladder cancer (Ta, T1) after transurethral resection (TUR) is frequent, adjuvant therapy to reduce the recurrence rate has been extensively investigated. Although intravesical chemotherapy has been employed for 30 years or more, neither the exact effect on the bladder epithelium nor the optimal dose and administration schedule has yet been clarified. In recent years, several derivatives of Adriamycin (ADR) have been developed, and 4′-epirubicin (FARM) is one of them. This drug has been shown to have antitumor effects almost equal to those of ADR and to produce less toxicity when given systemically as chemotherapy. In an attempt to clarify the effect of intravesical FARM in the prevention of recurrence of superficial bladder cancer, we conducted a prospective randomized trial to compare the effects of equal doses of FARM and ADR given by intravesical instillation after TUR in cases of highly recurrent superficial bladder cancer. A total of 73 patients with recurrent superficial bladder cancer were randomized to receive TUR and either 30 mg FARM or 30 mg ADR by intravesical instillation every 2–4 weeks for 1 year. The prophylactic effect on recurrence and the toxic effects of these drugs were investigated. The current results show that FARM provides efficacy almost equal to that of ADR in the prevention of recurrence in these patients. However, FARM also caused almost the same local toxic effects (bladder irritation, among others) as ADR. On the basis of these preliminary results, FARM is surmised to be one of the agents as beneficial as ADR in the prevention of recurrence of superficial bladder cancer.
Similar content being viewed by others
Abbreviations
- ADR:
-
Adriamycin
- FARM:
-
Farmorubicin (4′-epirubicin)
References
Akaza H, Koiso K, Kotake T, Matsumura Y, Isaka S, Machida T, Obata K, Ohashi Y, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Kagawa S, Niijima T, Japanese Urological Cancer Research Group for Adriamycin (1992) Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30 [Suppl]:S15
Blinst Italian Cooperative Group (1984) Intravesical doxorubicin for the prophylaxis of superficial bladder cancer. Cancer 54: 756
Bonfante B, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epidoxorubicin. Tumori 68: 105
Flanigan RC, Elison MF, Butler KM, Gomelia LG, McRoberts JW (1986) A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers. J Urol 136: 35
Ganzina F (1983) 4′-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10: 1
Giuliani FC, Coirin AK, Rice MR, Kaplan NO (1981) Effect of 4′-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice. Cancer Treat Rep 65: 1063
Hirano Y, Okajima E, Ozono S, Samma S, Sasaki K, Hiramatsu T, Babaya K, Watanabe S, Maruyama Y (1992) A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer—intravesical thio-TEPA versus oral UFT. Cancer Chemother Pharmacol 30 [Suppl]: S26
Kubota Y, Noguchi S, Shuin T, Moriyama M, Hosaka M, Satomi Y, Furuhata A, Kondo I, Sakuramoto T, Yao M, Fukushima S (1987) Preoperative doxorubicin instillation in recurrent superficial bladder cancer. Cancer Chemother Pharmacol 20 [Suppl]: S56
Niijima T, Koiso K, Akaza H, the Japanese Urological Cancer Research Group for Adriamycin (1983) Randomized clinical trial chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]: S79
Omoto T, Masaki Z, Kano M, Morita I, Ariyoshi A, Ishizawa N, Momose S (1982) Postoperative intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. Urology 20: 510
Pagano F, Garbegilo A, Milani C, Bassi P, Pegoraro V (1987) Prognosis of bladder cancers. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13: 145
Schulman CC, Denis LJ, Oosterlinck W, De Sy W, Chantrie M, Bouffioux C, Van Changh PJ, Van Erps P (1983) Early adjuvant Adriamycin in superficial bladder carcinoma. World J Urol 1: 86
Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 461
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shuin, T., Kubota, Y., Noguchi, S. et al. A phase II study of prophylactic intravesical chemotherapy with 4′-epirubicin in recurrent superficial bladder cancer: comparison of 4′-epirubicin and Adriamycin. Cancer Chemother. Pharmacol. 35 (Suppl 1), S52–S56 (1994). https://doi.org/10.1007/BF00686920
Issue Date:
DOI: https://doi.org/10.1007/BF00686920